A novel MGB probe-based assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPMI (nucleophosmin) exon 12 mutations
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F08%3A00027835" target="_blank" >RIV/00216224:14110/08:00027835 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
A novel MGB probe-based assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPMI (nucleophosmin) exon 12 mutations
Original language description
Insertions into exon 12 of NPM1 gene represent the most frequent molecular aberration in the subgroup of patients with AML otherwise showing normal karyotype. Therefore, NPM1 mutations may be used as a marker for quantification of minimal residual disease (MRD). Here we propose highly sensitive and reproducible MGB probe-based method for MRD.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2008
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů